CER study of thrombus for injection (lyophilized) based on real-world clinical medical big data
- Conditions
- Cerebral infarction
- Registration Number
- ITMCTR2000003520
- Lead Sponsor
- The First Affiliated Hospital of Henan University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
All hospitalized patients with the first diagnosis of cerebral infarction.
1. Patients with severe liver damage, including patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= more than 2 times the upper limit of normal value, and AST/ALT>1;
2. Patients with severe renal impairment and patients with serum creatinine >= 3 times the normal value;
3. Patients with secondary cerebral embolism caused by tumors, brain trauma, brain parasites, rheumatic heart disease, atrial fibrillation;
4. Patients with multiple organ failure;
5. Inpatients using XST for less than 5 days or continuous medication for more than 15 days;
6. Use inpatients with too large or too small dose of XST;
7. XST is used in the Chinese medicine hospital, but it is an inpatient with non-blood stasis syndrome;
8. There is no relevant description of the treatment effect of cerebral infarction in the medical record;
9. XST used for treatment is not manufactured by Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms;endpoint efficacy index;NIHSS score;TCM syndrome score;clinical signs;
- Secondary Outcome Measures
Name Time Method